SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act 1934
Date of Report: February 2, 2004
Titan Pharmaceuticals, Inc.
(Exact name of registrant as specified in
charter)
Delaware
(State or other jurisdiction of
incorporation)
|
0-27436 |
|
94-3171940 |
|
(Commission File Number) |
|
(IRS Employer Identification No.) |
|
400 Oyster Point Blvd., Suite 505, South San Francisco, California 94080 |
||
|
(Address of principal executive offices) (Zip Code) |
||
Registrant's telephone number, including area code: (650) 244-4990
Item 5. Other Events
On February 2, 2004, we announced that all of the class action and derivative lawsuits filed against Titan have been dismissed without prejudice.
Reference is made to the related press release filed as Exhibit 20.1 hereto, which is incorporated by reference herein.
Item 7. Financial Statements, Pro Forma Financial Information and Exhibits
(c) Exhibits
20.1 Press Release dated February 2, 2004
.
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
TITAN PHARMACEUTICALS, INC. |
||
|
|
By: |
/s/ Robert E. Farrell |
|
Robert E. Farrell, Executive Vice President |
||
Dated: February 3, 2004